West Pharmaceutical Services Welcomes Robert McMahon
West Pharmaceutical Services, Inc. (NYSE: WST), a leader in injectable drug administration solutions, has recently appointed Robert McMahon as the new Chief Financial Officer (CFO), starting on August 4, 2025. Mr. McMahon takes over the CFO role from Bernard Birkett, who will transition to a Senior Advisor position to assist during this change.
A Seasoned Executive Ready to Lead
Eric M. Green, President and Chief Executive Officer of West, expressed his confidence in Mr. McMahon's abilities, stating, "Bob is an accomplished CFO and seasoned executive within the healthcare industry. His extensive experience includes guiding companies through significant financial transformations and delivering remarkable results. With a 34-year career, Bob has a proven record of not just achieving but exceeding financial goals. We believe his leadership will be key in navigating the company's future growth and enhancing shareholder value.”
McMahon's Impressive Background
Mr. McMahon joins West from Agilent Technologies Inc., where he has served as CFO since 2018. His responsibilities at Agilent included finance, audit, treasury, tax, investor relations, IT, and procurement. Before his time at Agilent, he held the CFO position at Hologic, Inc. and dedicated 20 years to Johnson & Johnson, taking on significant financial roles. Additionally, he has been an Independent Director at OraSure Technologies, Inc. since 2023.
Looking Forward to Future Opportunities
Expressing his enthusiasm for the new role, Mr. McMahon stated, "I’m excited by the opportunity to join such a well-positioned company with a talented team dedicated to improving patient health. With over a century of innovation at its core, I look forward to collaborating with Eric and the leadership group to significantly influence West’s growth narrative and serve our stakeholders effectively.”
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. stands out as a leading provider of top-notch injectable solutions and services, committed to enhancing patient care. They partner with both established and emerging drug developers to ensure the effective and safe delivery of vital medications. West's global team consists of more than 10,000 individuals across 50 locations, including 25 manufacturing sites worldwide, facilitating the distribution of over 41 billion components and devices annually.
Recent Financial Performance
In the preceding fiscal year, West garnered $2.89 billion in net sales. The company is publicly traded on the New York Stock Exchange as WST and is listed on the esteemed Standard & Poor's 500 index. For further insights into the organization's operations and offerings, visiting their official website is highly recommended.
Frequently Asked Questions
Who is Robert McMahon?
Robert McMahon is the newly appointed Chief Financial Officer of West Pharmaceutical Services, Inc.
When will Robert McMahon start his position?
He will officially take over the CFO role on August 4, 2025.
What experience does McMahon bring to West?
McMahon has over 34 years of experience in the healthcare industry, with notable positions at Agilent Technologies, Hologic, and Johnson & Johnson.
Why is Bernard Birkett stepping down?
Bernard Birkett is transitioning to a Senior Advisor role after announcing his retirement as CFO.
What does West Pharmaceutical Services do?
West is a prominent provider of injectable solutions and services for drug developers, ensuring the safe administration of medications.
